CASI Pharmaceuticals Fundamentals

CASI
 Stock
  

USD 1.97  0.02  1.01%   

CASI Pharmaceuticals fundamentals help investors to digest information that contributes to CASI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of CASI Pharmaceuticals Stock. The fundamental analysis module provides a way to measure CASI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CASI Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
CASI Pharmaceuticals Gross Profit is most likely to increase significantly in the upcoming years. The last year's value of Gross Profit was reported at 17.61 Million. The current Interest Expense is estimated to increase to about 24.1 K, while Consolidated Income is projected to decrease to (36.8 M).

CASI Pharmaceuticals Shares Owned by Institutions Analysis

CASI Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
 2016 2020 2021 2022 (projected)
Revenues USD4.13 M15.14 M30.17 M32.55 M
Revenues4.13 M15.14 M30.17 M32.55 M
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
More About Shares Owned by Institutions | All Equity Analysis

Current CASI Pharmaceuticals Shares Owned by Institutions

    
  14.82 %  
Most of CASI Pharmaceuticals' fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CASI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 14.821% of CASI Pharmaceuticals are shares owned by institutions. This is 66.8% lower than that of the Biotechnology sector and 68.8% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 62.2% higher than that of the company.

CASI Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining CASI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare CASI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CASI Pharmaceuticals competition to find correlations between indicators driving CASI Pharmaceuticals's intrinsic value. More Info.
CASI Pharmaceuticals is number one stock in market capitalization category among related companies. It is number one stock in current liabilities category among related companies creating about  0.13  of Current Liabilities per Market Capitalization. The ratio of Market Capitalization to Current Liabilities for CASI Pharmaceuticals is roughly  7.71 . CASI Pharmaceuticals Market Capitalization is most likely to increase significantly in the upcoming years. The last year's value of Market Capitalization was reported at 111.84 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value CASI Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CASI Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CASI Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

CASI Pharmaceuticals Target Price Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CASI Pharmaceuticals' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics of similar companies.
CASI Pharmaceuticals is currently under evaluation in target price category among related companies.

CASI Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of CASI Pharmaceuticals from analyzing CASI Pharmaceuticals' financial statements. These drivers represent accounts that assess CASI Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CASI Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(215.4 K)(219.77 K)(368.26 K)(334.41 K)(208.26 K)(224.7 K)
Average Assets29.53 M98.15 M114.96 M113.26 M141.8 M152.99 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(10.65 M)(25.84 M)(44.27 M)(46.42 M)(35.7 M)(38.51 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(10.65 M)(25.8 M)(43.45 M)(45.06 M)(33.56 M)(34.44 M)
Earnings before Tax(10.77 M)(27.47 M)(46.03 M)(48.29 M)(36.65 M)(37.62 M)
Average Equity22.6 M93.48 M86.65 M76.69 M91.49 M98.71 M
Enterprise Value191.32 M278.85 M234.47 M291.04 M59.8 M61.37 M
Free Cash Flow(7.34 M)(29.71 M)(30.3 M)(24.68 M)(35.78 M)(36.72 M)
Invested Capital(1.95 M)8.05 M27.39 M50.78 M74.2 M80.06 M
Invested Capital Average(942.69 K)3.2 M20.61 M35.75 M64.69 M69.8 M
Market Capitalization211.47 M376.22 M297.71 M365.63 M111.84 M142.77 M
Tangible Asset Value45.1 M94.63 M88.96 M114.52 M126.09 M136.05 M
Working Capital38.75 M88.69 M56.77 M66.05 M48.78 M44.9 M

CASI Pharmaceuticals Fundamentals

About CASI Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CASI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CASI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CASI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue2.8 MM
Cost of Revenue12.6 M13.5 M
Revenues30.2 M32.5 M
Revenue to Assets 0.22  0.23 
Revenue Per Employee171.4 K154.9 K
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CASI Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CASI Pharmaceuticals' short interest history, or implied volatility extrapolated from CASI Pharmaceuticals options trading.

Pair Trading with CASI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CASI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CASI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to CASI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CASI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CASI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CASI Pharmaceuticals to buy it.
The correlation of CASI Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CASI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CASI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CASI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CASI Pharmaceuticals Piotroski F Score and CASI Pharmaceuticals Altman Z Score analysis. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
27.1 M
Quarterly Revenue Growth YOY
0.26
Return On Assets
(0.15) 
Return On Equity
(0.27) 
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.